Novaliq conducts a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid drug development program in collaboration with the university of Cologne, germany

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach in collaboration with the University of Cologne, Germany. DED is one of the most…